Regnante Keith
SEC CIK 1682068 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | CFO | 39.3K | — | $5.56M | 8 | 2023-06-08 | 2026-02-18 |
Most active insiders at KROS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneeberger Daniel | 10% | — | $95.66M |
| 2 | Pontifax (China) IV L.P. | 10% | — | $84.98M |
| 3 | Cho Esther | SVP, GC | — | $123.7K |
| 4 | Seehra Jasbir | CEO, Dir | — | $113.4K |
| 5 | Lerner Lorena Raquel | CSO | — | $100.0K |
| 6 | Regnante Keith | CFO | — | $77.5K |
| 7 | BIENAIME JEAN JACQUES | Dir | $75.8K | — |
| 8 | Knowles Julius | Dir | — | $28.2K |
| 9 | Farzan Nima | Dir | — | $28.2K |
| 10 | Seth Alpna | Dir | — | $28.1K |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | 2026-02-18 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale | $16.35 | -4,739 | 39.3K | -11% | -$77.5K | |
| 2025-02-19 | 2025-02-18 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | A - Grant | $0.00 | +44.0K | 44.0K | New | $0 | |
| A | 2025-01-24 | 2024-01-04 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40.0K | 0 | -100% | -$1.81M |
| A | 2025-01-24 | 2024-01-04 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 40.0K | New | +$640.0K |
| D | 2024-01-08 | 2023-11-04 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 40.0K | New | +$640.0K |
| D | 2024-01-08 | 2023-11-04 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40.0K | 0 | -100% | -$1.81M |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 20.0K | New | +$640.0K |
| DM | 2023-06-12 | 2023-06-08+ | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale+OE | $46.61 | -40.0K | 2,699 | -94% | -$1.86M |
Purchase Sale Sale after option exercise All abbreviations